By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Biotechnology are discussed in a new report. According to news originating from Frederick, Maryland, by NewsRx correspondents, research stated, "The cancer stem cell marker, EpCAM, is an important indicator of Wnt/?-catenin signaling activation and a functional component of hepatocellular tumor-initiating cells. A high-throughput screening assay was developed to identify inhibitors of EpCAM-dependent growth of hepatocellular carcinoma (HCC) cells."
Our news journalists obtained a quote from the research from National Cancer Institute, "EpCAM(+) and EpCAM(-) HCC cell lines were assessed for differential sensitivity to a Wnt/?-catenin pathway inhibitor. Libraries comprising 22 668 pure compounds and 107 741 crude or partially purified natural product extracts were tested, and 12 pure compounds and 67 natural product extracts were identified for further study. Three active compounds and the positive control were further characterized in terms of effects on EpCAM expression. Treatment of EpCAM(+) Hep3B cells resulted in loss of EpCAM expression as assessed by flow cytometry. This reduction was incomplete (most cells continued to express EpCAM), but resulted in generation of cell populations expressing lower levels of EpCAM. Sublethal concentrations (~IC50 ) reduced median EpCAM expression to 28% of control after 1 day and 19% of control after 2 days. Reduction in EpCAM expression preceded growth inhibition suggesting that a threshold of EpCAM expression may be required for growth of EpCAM-dependent cells."
According to the news editors, the research concluded: "The identification of compounds with a variety of possible molecular targets suggests a likelihood of multiple mechanisms for modulation of EpCAM-dependent cell growth."
For more information on this research see: High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells. Chemical Biology & Drug Design, 2013;82(2):131-9. Chemical Biology & Drug Design can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA. (Wiley-Blackwell - www.wiley.com/; Chemical Biology & Drug Design - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1747-0285)
The news correspondents report that additional information may be obtained from C.J. Henrich, Molecular Targets Laboratory, National Cancer Institute, Frederick, MD, United States. Additional authors for this research include A. Budhu, Z. Yu, J.R. Evans, E.I. Goncharova, T.T. Ransom, X.W. Wang and J.B McMahon (see also technology.html">Biotechnology).
The publisher's contact information for the journal Chemical Biology & Drug Design is: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.
Keywords for this news article include: Biotechnology, Maryland, Oncology, Frederick, United States, Cancer Gene Therapy, Hepatocellular Carcinoma, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC